Acquired Nisin Resistance in Staphylococcus aureus Involves Constitutive Activation of an Intrinsic Peptide Antibiotic Detoxification Module
Open Access
- 26 December 2018
- journal article
- research article
- Published by American Society for Microbiology in mSphere
- Vol. 3 (6)
Abstract
NIS and related bacteriocins are of interest as candidates for the treatment of human infections caused by Gram-positive pathogens such as Staphylococcus aureus . An important liability of NIS in this regard is the ease with which S. aureus acquires resistance. Here we establish that this organism naturally possesses the cellular machinery to detoxify NIS but that the ABC transporter responsible (VraDE) is not ordinarily produced to a degree sufficient to yield substantial resistance. Acquired NIS resistance mutations prompt activation of the regulatory circuit controlling expression of vraDE , thereby unmasking an intrinsic resistance determinant. Our results provide new insights into the complex mechanism by which expression of vraDE is regulated and suggest that a potential route to overcoming the resistance liability of NIS could involve chemical modification of the molecule to prevent its recognition by the VraDE transporter.Keywords
This publication has 37 references indexed in Scilit:
- Biomedical applications of nisinJournal of Applied Microbiology, 2015
- Corrigendum: Antibacterial activities of bacteriocins: application in foods and pharmaceuticalsFrontiers in Microbiology, 2014
- An In Vitro Study on the Effects of Nisin on the Antibacterial Activities of 18 Antibiotics against Enterococcus faecalisPLOS ONE, 2014
- Bacteriocins — a viable alternative to antibiotics?Nature Reviews Microbiology, 2012
- Bacitracin and nisin resistance in Staphylococcus aureus: a novel pathway involving the BraS/BraR two‐component system (SA2417/SA2418) and both the BraD/BraE and VraD/VraE ABC transportersMolecular Microbiology, 2011
- In Vitro Studies Indicate a High Resistance Potential for the Lantibiotic Nisin in Staphylococcus aureus and Define a Genetic Basis for Nisin ResistanceAntimicrobial Agents and Chemotherapy, 2011
- Lipid II as a target for antibioticsNature Reviews Drug Discovery, 2006
- Bacteriocins: developing innate immunity for foodNature Reviews Microbiology, 2005
- Lantibiotics: structure, biosynthesis and mode of actionFEMS Microbiology Reviews, 2001
- NISIN IN EXPERIMENTAL TUBERCULOSISThe Lancet, 1952